Granulocyte macrophage colony-stimulating factor: current practice and novel approaches

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Endogenous myeloid colony-stimulating factors (CSFs) are crucial for managing immunosuppressed cancer patients.
• These factors significantly reduce chemotherapy-related infections, antibiotic use, hospital stays, and mortality.
• Two main recombinant myeloid CSFs, GM-CSF and G-CSF, are manufactured for clinical use.

Purpose of the Study:

• To review the clinical applications and benefits of endogenous myeloid CSFs in cancer care.
• To differentiate the mechanisms and clinical effects of GM-CSF and G-CSF.
• To highlight the multifaceted therapeutic potential of GM-CSF.

Main Methods:

• Review of clinical trials and scientific literature on myeloid CSFs.
• Comparison of the biological activities of GM-CSF and G-CSF.
• Analysis of clinical outcomes associated with CSF administration in cancer patients.

Main Results:

• GM-CSF (sargramostim) broadly influences myeloid progenitor cells, while G-CSF (filgrastim) selectively targets granulocytes.
• Clinical trials indicate GM-CSF provides benefits beyond neutrophil recovery.
• GM-CSF has shown potential in shortening mucositis and diarrhea, stimulating dendritic cells, and acting as an adjuvant vaccine agent.

Conclusions:

• Endogenous myeloid CSFs are vital in enhancing the management of immunosuppressed cancer patients.
• GM-CSF demonstrates a wider range of clinical benefits compared to G-CSF, including potential antitumor effects.
• Further research into GM-CSF's multifaceted roles may expand its therapeutic applications in oncology.